肝细胞癌的基因治疗:最新进展

Journal of Biomedicine (Sydney, NSW) Pub Date : 2019-01-01 DOI:10.7150/jbm.29161

C. Kosmidis, G. Koimtzis, G. Pantos, S. Atmatzidis, E. Pavlidis, M. Kosmidou, C. Efthimiadis, G. Anthimidis, N. Varsamis, Eleni Georgakoudi, A. Tsakalidis, I. Koskinas, A. Paraschou, Konstantina Tsopouridou, Nikos Tteralli, T. Koletsa, Katerina Zarampouka, Isaac I. Kesisoglou, K. Sapalidis, P. Zarogoulidis

{"title":"肝细胞癌的基因治疗:最新进展","authors":"C. Kosmidis, G. Koimtzis, G. Pantos, S. Atmatzidis, E. Pavlidis, M. Kosmidou, C. Efthimiadis, G. Anthimidis, N. Varsamis, Eleni Georgakoudi, A. Tsakalidis, I. Koskinas, A. Paraschou, Konstantina Tsopouridou, Nikos Tteralli, T. Koletsa, Katerina Zarampouka, Isaac I. Kesisoglou, K. Sapalidis, P. Zarogoulidis","doi":"10.7150/jbm.29161","DOIUrl":null,"url":null,"abstract":"Current statistics indicate that hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related death. Major predisposing conditions are hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. To date treatment approach includes liver transplantation, surgical resection and or ablation, however; recurrence, metastasis, and mortality still remains high. Therefore, alternative treatments such as gene therapy is increasingly being considered as a feasible proposal. In this mini review we will focus on novel data of the past 10 years on the subject of gene therapy and hepatocellular carcinoma.","PeriodicalId":91898,"journal":{"name":"Journal of Biomedicine (Sydney, NSW)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Gene Therapy for Hepatocellular Carcinoma: An Update\",\"authors\":\"C. Kosmidis, G. Koimtzis, G. Pantos, S. Atmatzidis, E. Pavlidis, M. Kosmidou, C. Efthimiadis, G. Anthimidis, N. Varsamis, Eleni Georgakoudi, A. Tsakalidis, I. Koskinas, A. Paraschou, Konstantina Tsopouridou, Nikos Tteralli, T. Koletsa, Katerina Zarampouka, Isaac I. Kesisoglou, K. Sapalidis, P. Zarogoulidis\",\"doi\":\"10.7150/jbm.29161\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Current statistics indicate that hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related death. Major predisposing conditions are hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. To date treatment approach includes liver transplantation, surgical resection and or ablation, however; recurrence, metastasis, and mortality still remains high. Therefore, alternative treatments such as gene therapy is increasingly being considered as a feasible proposal. In this mini review we will focus on novel data of the past 10 years on the subject of gene therapy and hepatocellular carcinoma.\",\"PeriodicalId\":91898,\"journal\":{\"name\":\"Journal of Biomedicine (Sydney, NSW)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biomedicine (Sydney, NSW)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7150/jbm.29161\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomedicine (Sydney, NSW)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7150/jbm.29161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

摘要

目前的统计数据表明，肝细胞癌(HCC)是世界上第五大最常见的恶性肿瘤，也是癌症相关死亡的第三大原因。主要的易感因素是乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染。然而，迄今为止的治疗方法包括肝移植、手术切除和/或消融;复发、转移和死亡率仍然很高。因此，基因治疗等替代疗法越来越被认为是一种可行的建议。在这篇小型综述中，我们将重点介绍过去10年来基因治疗和肝细胞癌的新数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Gene Therapy for Hepatocellular Carcinoma: An Update

Current statistics indicate that hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related death. Major predisposing conditions are hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. To date treatment approach includes liver transplantation, surgical resection and or ablation, however; recurrence, metastasis, and mortality still remains high. Therefore, alternative treatments such as gene therapy is increasingly being considered as a feasible proposal. In this mini review we will focus on novel data of the past 10 years on the subject of gene therapy and hepatocellular carcinoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Biomedicine (Sydney, NSW)

自引率

0.00%

发文量